Arvinas, Inc - ARVN STOCK NEWS

Arvinas, a clinical-stage biotechnology company, will present an overview at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 1:30 p.m. PT in San Francisco. CEO John Houston will lead the presentation, focusing on the company's innovative approach to targeted protein degradation. Arvinas utilizes its proprietary PROTAC® Discovery Engine to develop therapies aimed at devastating diseases, including investigational programs for metastatic prostate and breast cancer. A live audio webcast of the presentation will be available online.

Arvinas, a clinical-stage biotechnology firm, announces the resignation of Brad Margus from its Board, with Everett Cunningham appointed as his replacement. Margus was a valued member of the Audit Committee, contributing significantly to Arvinas' development. Cunningham brings over 25 years of experience in pharmaceuticals, previously holding key roles at Exact Sciences and GE Healthcare. With expertise in commercialization and a strong background in medical services, Cunningham is expected to enhance Arvinas’ transition into late-stage development and improve patient outcomes.

ARV-471, a novel PROTAC® estrogen receptor degrader, exhibits promising activity in patients with advanced ER+/HER2- breast cancer, achieving a median progression-free survival of 3.7 months overall and 5.7 months in patients with ESR1 mutant tumors. A clinical benefit rate of 38% was recorded in a heavily pre-treated cohort. Initial results from the VERITAC trial support the initiation of two Phase 3 trials. The study emphasizes ARV-471's favorable tolerability profile and potential as a new standard of care, with plans to initiate pivotal trials in late 2022 and early 2023.

Arvinas, Inc. (Nasdaq: ARVN) reported its third-quarter financial results for 2022, highlighting significant progress in clinical trials and executive team enhancements. The company is set to initiate two Phase 3 trials of ARV-471 for metastatic breast cancer by the year's end. Financially, revenues climbed to $30.3 million from $9.3 million in Q3 2021, driven by the ARV-471 collaboration. However, the net loss rose to $66.2 million, up from $46.8 million year-over-year, primarily due to increased R&D and administrative expenses.

Arvinas, a clinical-stage biotechnology company, will present at two key conferences in November 2022. At the Society for Neuroscience Annual Meeting, Angela Cacace will showcase research on PROTAC^® molecules targeting neurodegenerative proteins on November 12. Additionally, Arvinas will participate in the Stifel Healthcare Conference with Ron Peck and Randy Teel engaging in a fireside chat on November 15. The company focuses on innovative therapies that degrade disease-causing proteins, currently advancing multiple clinical-stage programs, including treatments for prostate and breast cancer.

Arvinas, Inc. (Nasdaq: ARVN) announced the appointment of Paul McInulty as Senior Vice President of Regulatory Affairs, effective October 3, 2022. McInulty brings over 25 years of biopharmaceutical experience, having previously held key roles at Bristol Myers Squibb and Celgene Corporation. His expertise will support Arvinas' transition into a late-stage development company focused on targeted protein degradation therapies. With a robust pipeline, including investigational programs for metastatic prostate and breast cancer, Arvinas aims to leverage McInulty’s experience to enhance regulatory strategies and overall growth trajectory.

On September 30, 2022, Arvinas, a clinical-stage biotechnology company, held its inaugural “Arvinas Impact Day,” with nearly 200 employees volunteering in the Greater New Haven area. The event emphasized community service, focusing on STEM initiatives and environmental protection. Highlights included educating over 300 students on financial literacy, enhancing facilities for a non-profit organization, and cleaning local beaches. CEO John Houston emphasized the company's commitment to community engagement and expressed enthusiasm for future initiatives.

Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, announced participation in a fireside chat at the Bank of America Securities Precision Oncology Conference on October 3, 2022, at 10:40 a.m. ET. The event will be accessible via a live audio webcast on Arvinas' website. The company is known for its innovative PROTAC® platform, which develops therapies aimed at degrading disease-causing proteins. Arvinas has several clinical-stage programs targeting prostate and breast cancers, reinforcing its commitment to advancing treatment options for severe diseases.